Journal: Journal of Experimental & Clinical Cancer Research : CR

Article Title: Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation

doi: 10.1186/s13046-020-01796-4

Figure Lengend Snippet: Clinical impact of AChE in the R0 resectable, transgenic pancreatic cancer mouse model and in human PCa. a - b Plasmids containing the Sleeping Beauty (SB) transposase SB13, a Kras-G12V encoding transposon, and the Cre recombinase were injected and electroporated into the pancreatic tail of p53floxed mice ( p53 fl/fl ). (Pfl model). For details on plasmid constructs, please refer to . c - d After pancreatectomy and adjuvant chemotherapy with gemcitabine, mice of the Pfl-genotype exhibited a median survival of 41 days. Combinational therapy of pancreatectomy with adjuvant gemcitabine and physostigmin led to a median survival of 32 days, and with adjuvant gemcitabine and pyridostigmine to 39 days (n.s.: not significant). e Survival rate of PCa patients with high ( n = 19) and low ( n = 20) AChE presence based on median immunohistochemistry/IHC-Score (n.s., log-rank test.). Kaplan-Meier analysis did not reveal a significant difference in survival between both groups. f Correlation analysis (linear regression) of cancer tissue AChE expression based on semiquantitative IHC score and UICC tumor stage (n.s.: not significant). g Correlation of semiquantitative immunohistochemistry (IHC) scores for AChE expression and tumor grading (G1-G3). (G1 vs. G2 ** p = 0.018; G1 vs. G3 ** p = 0.015; Mann-Whitney U test). h Correlation analysis (linear regression) of ChAT expression within nerves of human PCa tissues based on semiquantitative IHC score and UICC tumor stage. Graph shows a negative correlation between ChAT expression and tumor stage, indicating that low ChAT expression is correlated to higher tumor stages, while high ChAT expression correlates to low tumor stages (r 2 = 0.1988, p = 0.048)

Article Snippet: Using this model, we applied adjuvant chemotherapy combining gemcitabine with either physostigmine (at 0.2xLD 50 , i.e. 160 μg/kg, http://datasheets.scbt.com/sc-252784.pdf ), or with pyridostigmine (0.2xLD 50 , i.e. 520 μg/kg, http://www.vetpharm.uzh.ch/reloader.htm?wir/00000015/5975_08.htm?wir/00000015/5975_00.htm ), applied s.c. three times a week.

Techniques: Transgenic Assay, Injection, Plasmid Preparation, Construct, Adjuvant, Immunohistochemistry, Expressing, MANN-WHITNEY

Journal: Cell and Tissue Banking

Article Title: The promising approach of MSCs therapy for COVID-19 treatment

doi: 10.1007/s10561-022-10060-2

Figure Lengend Snippet: The MSCs therapy functional mechanism for COVID-19 treatment

Article Snippet: NCT04492501 , Role of investigational therapies alone or in combination to treat moderate, severe and critical COVID-19 , UNICEF/Pakistan , 600 , Procedure: Therapeutic plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: MSC therapy , Not Applicable , In an attempt to treat COVID-19, investigator used different investigational treatment either alone or in combination to see mortality and morbidity benefit on the basis of limited evidence available so far. These investigational modalities included therapeutic plasma exchange, convalescent plasma, remdesivir, tocilizumab and MSC therapy in addition to standard supportive treatment..

Techniques: Functional Assay

Journal: Cell and Tissue Banking

Article Title: The promising approach of MSCs therapy for COVID-19 treatment

doi: 10.1007/s10561-022-10060-2

Figure Lengend Snippet: Summarized clinical trial (marked “completed”) studies on the MSCs in the COVID-19 ( https://www.clinicaltrials.gov )

Article Snippet: NCT04492501 , Role of investigational therapies alone or in combination to treat moderate, severe and critical COVID-19 , UNICEF/Pakistan , 600 , Procedure: Therapeutic plasma exchange Biological: Convalescent Plasma Drug: Tocilizumab Drug: Remdesivir Biological: MSC therapy , Not Applicable , In an attempt to treat COVID-19, investigator used different investigational treatment either alone or in combination to see mortality and morbidity benefit on the basis of limited evidence available so far. These investigational modalities included therapeutic plasma exchange, convalescent plasma, remdesivir, tocilizumab and MSC therapy in addition to standard supportive treatment..

Techniques: Injection, Marker, Real-time Polymerase Chain Reaction, Transplantation Assay, Infection, Modification, Ex Vivo, Derivative Assay, Flow Cytometry

Journal: Pharmacy and Therapeutics

Article Title: Ledipasvir/Sofosbuvir (Harvoni): Improving Options for Hepatitis C Virus Infection

doi:

Figure Lengend Snippet: Comparison of Class I, Level A Recommendations: Harvoni and Viekira Pak 18 – 20 , 26 – 28

Article Snippet: Brief Summary of HCV Treatment Guidelines in Patients Who Are HCV Genotype 1–Positive And Failed Prior PEG/RBV Therapy 25 table ft1 table-wrap mode="anchored" t5 Table 3 caption a7 Harvoni (LDV/SOF) Viekira Pak (OBV/PTV/r + DSV ± RBV) Trial Name ION I ION II ION III SAPPHIRE I PEARL III PEARL IV TURQUOISE II Study population Treatment-naïve GT 1 null-responders Treatment-naïve with no cirrhosis Treatment-naïve with no cirrhosis GT 1b treatment-naïve with no cirrhosis GT 1a treatment-naïve with no cirrhosis Compensated cirrhosis Treatment regimen LDV/SOF ± RBV LDV/SOF ± RBV LDV/SOF ± RBV OBV/PTV/r + DSV + RBV OBV/PTV/r + DSV ± RBV OBV/PTV/r + DSV ± RBV OBV/PTV/r + DSV + RBV Number of patients enrolled 865 440 647 631 419 305 380 Treatment duration 12 or 24 weeks 12 or 24 weeks 8 or 12 weeks 12 weeks 12 weeks 12 weeks 12 or 24 weeks SVR12 97%–99% 94%–99% 93%–95% 96.2% 99.5%–99.0% 90.2%–97% 91.8%–95.9% Relapse 2 11 23 7 1 11 13 Breakthrough 0 1 0 1 0 7 4 Discontinuation due to adverse events 0 0 3 4 0 2 8 Open in a separate window DSV = dasabuvir; GT = genotype; LDV = ledipasvir; OBV = ombitasvir; PTV = paritaprevir; r = ritonavir; RBV = ribavirin; SOF = sofosbuvir; SVR12 = sustained virological response 12 weeks after treatment Comparison of Class I, Level A Recommendations: Harvoni and Viekira Pak 18 – 20 , 26 – 28

Techniques: